The metabolite of a drug that is helping patients battle multiple sclerosis appears to significantly slow the onset of Parkinson’s disease, researchers say.
The metabolite of a drug that is helping patients battle multiple sclerosis appears to significantly slow the onset of Parkinson’s disease, researchers say.